PYC THERAPEUTICS LIMITED - Announcements

6.43%

$1.33

Market Cap $772.8M

Healthcare Biotechnology

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

PYC	Quarterly Activities and Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/22	212.81KB	Share
PYC	Successful Completion of Key Translational Milestone	PRICE SENSITIVE	16/11/21	190.99KB	Share
PYC	Trading Halt	PRICE SENSITIVE	15/11/21	186.73KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	287.47KB	Share
PYC	Retina Target Engagement Confirmed in Large Eye	PRICE SENSITIVE	29/09/21	316.13KB	Share
PYC	Preliminary Final Report	PRICE SENSITIVE	31/08/21	3.64MB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/21	407.7KB	Share
PYC	Second Drug Program Progressing Towards Human Trials	PRICE SENSITIVE	08/06/21	389.99KB	Share
PYC	Trading Halt	PRICE SENSITIVE	07/06/21	613.05KB	Share
PYC	March 2021 Quarterly Report and Cashflow	PRICE SENSITIVE	30/04/21	311.12KB	Share
PYC	Lead Investigational Drug Demonstrates Key Improvement	PRICE SENSITIVE	02/03/21	561.42KB	Share
PYC	Half Year Accounts and Appendix 4D	PRICE SENSITIVE	26/02/21	695.29KB	Share
PYC	Progress US Clinical Stage Company and Corporate Objectives	PRICE SENSITIVE	22/02/21	243.93KB	Share
PYC	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/01/21	424.49KB	Share
PYC	Visual Evidence of Lead Drugs Efficacy	PRICE SENSITIVE	16/12/20	302.88KB	Share
PYC	Review of Activities and Appendix 4C	PRICE SENSITIVE	26/10/20	230.99KB	Share
PYC	Successful Institutional Entitlement Offer and Placement	PRICE SENSITIVE	22/10/20	287.4KB	Share
PYC	PYC Business and Equity Raising Presentation	PRICE SENSITIVE	20/10/20	1.52MB	Share
PYC	PYC Equity Raising to Raise up to $55 Million	PRICE SENSITIVE	20/10/20	396.91KB	Share
PYC	Trading Halt	PRICE SENSITIVE	16/10/20	295.26KB	Share
PYC	New Drug for Substantial Unmet Need Added to Pipeline	PRICE SENSITIVE	12/10/20	228.7KB	Share
PYC	PYC's Lead Drug Effective in Patient Derived Models Tested	PRICE SENSITIVE	07/10/20	147.03KB	Share
PYC	Second Potential Blockbuster Drug Added to PYC's Pipeline	PRICE SENSITIVE	05/10/20	195.93KB	Share
PYC	Creation of Novel Gene Therapy Delivery Technology	PRICE SENSITIVE	08/09/20	256.32KB	Share
PYC	Appendix 4E Preliminary Final Report	PRICE SENSITIVE	31/08/20	343.8KB	Share
PYC	Executive re-structure across global operations	PRICE SENSITIVE	19/08/20	82.17KB	Share
PYC	Shareholder Update - Forward View 2020 Milestones	PRICE SENSITIVE	05/08/20	144.91KB	Share
PYC	June 2020 Quarterly Activity Report and Cashflow	PRICE SENSITIVE	30/07/20	196.06KB	Share
PYC	Successful Dose Response & Toxicity Studies in Lead Program	PRICE SENSITIVE	22/07/20	181.82KB	Share
PYC	S&P DJI Announces June 2020 Quarterly Rebalance	PRICE SENSITIVE	12/06/20	223.16KB	Share
PYC	March 2020 Quarterly Activities and Cash Flow Report	PRICE SENSITIVE	29/04/20	192.29KB	Share
PYC	Successful Efficacy Result on Path to First in Human Studies	PRICE SENSITIVE	01/04/20	564.48KB	Share
PYC	Trading Halt	PRICE SENSITIVE	30/03/20	301.8KB	Share
PYC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/20	580.54KB	Share
PYC	Investor Presentation - February 2020	PRICE SENSITIVE	24/02/20	2.07MB	Share
PYC	CEO Appointment and Establishment of US Office	PRICE SENSITIVE	12/02/20	125.02KB	Share
PYC	Expansion Of Drug Development Pipeline	PRICE SENSITIVE	03/02/20	116.07KB	Share
PYC	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	56.42KB	Share
PYC	Quarterly Shareholder Update	PRICE SENSITIVE	06/01/20	90.41KB	Share
PYC	Drug Delivery Greater Than 100% More Effective In Animals	PRICE SENSITIVE	02/12/19	213.35KB	Share
PYC	Conclusion of Genentech Antimicrobial Collaboration	PRICE SENSITIVE	15/11/19	237.67KB	Share
PYC	PYC Increases Shareholding in Vision Pharma	PRICE SENSITIVE	14/11/19	78.29KB	Share
PYC	Retail Offer Document	PRICE SENSITIVE	04/11/19	1.06MB	Share
PYC	PYC's Institutional Entitlement Offer Closes	PRICE SENSITIVE	04/11/19	79.57KB	Share
PYC	Entitlement Offer - Investor Presentation	PRICE SENSITIVE	31/10/19	882.77KB	Share
PYC	$26.8m Fully Underwritten Accelerated Entitlement Offer	PRICE SENSITIVE	31/10/19	104.39KB	Share
PYC	Trading Halt	PRICE SENSITIVE	31/10/19	116.66KB	Share
PYC	Sept 2019 Quarterly Shareholder Update and Appendix 4C	PRICE SENSITIVE	30/10/19	192.66KB	Share
PYC	Successful Major Milestone - Human Retina in a Dish Models	PRICE SENSITIVE	09/10/19	368.07KB	Share
PYC	Strategic Partnership and Lead Program	PRICE SENSITIVE	01/10/19	204.29KB	Share
PYC	Trading Halt	PRICE SENSITIVE	30/09/19	151.93KB	Share
PYC	Successful Time-Course Studies in Animals	PRICE SENSITIVE	25/09/19	85.62KB	Share
PYC	Successful Competitive Drug Evaluation in Animals	PRICE SENSITIVE	03/09/19	326.49KB	Share
PYC	Preliminary Final Report	PRICE SENSITIVE	30/08/19	300.77KB	Share
PYC	Successful Time - Course Studies in Animals	PRICE SENSITIVE	22/08/19	105.13KB	Share
PYC	Response to ASX Aware Query	PRICE SENSITIVE	07/08/19	738.05KB	Share
PYC	Phylogica's Technology is Effective in Human Cells	PRICE SENSITIVE	06/08/19	112.2KB	Share
PYC	Company Presentation - July 2019	PRICE SENSITIVE	24/07/19	1.38MB	Share
PYC	Operational Update and Appendix 4C	PRICE SENSITIVE	23/07/19	239.37KB	Share
PYC	Animal Models - 400% Outperformance of Gold Standard	PRICE SENSITIVE	23/07/19	93.57KB	Share
PYC	Break Through Animal Model Results	PRICE SENSITIVE	27/06/19	298.35KB	Share
PYC	March 2019 Quarterly Operational Update and App4C	PRICE SENSITIVE	29/04/19	130.46KB	Share
PYC	Collaboration Agreement - siRNA delivery	PRICE SENSITIVE	14/03/19	72.14KB	Share
PYC	Flagship Program - Successful Animal Models	PRICE SENSITIVE	12/03/19	90.4KB	Share
PYC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/19	629.87KB	Share
PYC	First Competitive Read Out - Peptide Vaccine	PRICE SENSITIVE	08/02/19	95.97KB	Share
PYC	Dec 2018 Operational Update and App4C	PRICE SENSITIVE	31/01/19	171.31KB	Share
PYC	CEO letter and Operational Update	PRICE SENSITIVE	17/01/19	385.08KB	Share
PYC	In Vivo Success - peptide vaccine (Amended Graphics)	PRICE SENSITIVE	06/12/18	149.91KB	Share
PYC	In vivo success - peptide vaccine in Herpes Simplex Virus	PRICE SENSITIVE	06/12/18	207.42KB	Share
PYC	Successful Delivery of CRIPR/Cas9 into Cells ex vivo	PRICE SENSITIVE	04/12/18	151.1KB	Share
PYC	FNA Presentation	PRICE SENSITIVE	23/11/18	1.8MB	Share
PYC	AGM Company Presentation	PRICE SENSITIVE	16/11/18	1.39MB	Share
PYC	Sept 2018 Quarterly Operations Update and App4C	PRICE SENSITIVE	31/10/18	177.33KB	Share
PYC	Fourfold Delivery Improvement in a New Lead Candidate	PRICE SENSITIVE	29/10/18	70.4KB	Share
PYC	R&D Tax Incentive Refund	PRICE SENSITIVE	08/10/18	63.48KB	Share
PYC	Reinstatement to Official Quotation	PRICE SENSITIVE	12/09/18	403.81KB	Share
PYC	Phylogica Recapitalisation	PRICE SENSITIVE	12/09/18	64.61KB	Share
PYC	Update on Capital Raising	PRICE SENSITIVE	11/09/18	65.78KB	Share
PYC	Suspension from Official Quotation	PRICE SENSITIVE	11/09/18	484.03KB	Share
PYC	Trading Halt	PRICE SENSITIVE	07/09/18	274.88KB	Share
PYC	Preliminary Final Report	PRICE SENSITIVE	31/08/18	282.38KB	Share
PYC	June 2018 Quarterly Operational Update and App4C	PRICE SENSITIVE	31/07/18	224.74KB	Share
PYC	Achievement of Major Milestone - In vivo Cre Delivery	PRICE SENSITIVE	30/07/18	80.79KB	Share
PYC	Successful In-vivo Results Peptide Vaccine T-Cell Expansion	PRICE SENSITIVE	27/07/18	70.3KB	Share
PYC	CEO Update	PRICE SENSITIVE	09/07/18	114.19KB	Share
PYC	March 2018 Operational Update and Cashflow	PRICE SENSITIVE	30/04/18	238.56KB	Share
PYC	Changes to Board and Management	PRICE SENSITIVE	11/04/18	35.65KB	Share
PYC	Trading Halt	PRICE SENSITIVE	09/04/18	141.58KB	Share
PYC	Cre Enzyme Delivery Provides Validation & Strategic Value	PRICE SENSITIVE	02/03/18	446.56KB	Share
PYC	Dec 2017 Half-year financial statements & Appendix 4D	PRICE SENSITIVE	28/02/18	511.86KB	Share
PYC	Dec Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/01/18	602.57KB	Share
PYC	Federal R&D Tax Credit Received	PRICE SENSITIVE	11/01/18	76.64KB	Share
PYC	FPP Results Effective in Delivering Peptide Cancer Vaccine	PRICE SENSITIVE	08/01/18	109.79KB	Share
PYC	Phylogica Strategic Update - Pivot to Platform	PRICE SENSITIVE	04/12/17	123.57KB	Share
PYC	Quarterly Update and Appendix 4C	PRICE SENSITIVE	25/10/17	139.47KB	Share
PYC	PYC Granted US Patent for Peptides Entering Brain Cells	PRICE SENSITIVE	04/10/17	65.89KB	Share
PYC	New Delivery Vehicles Show Improved Performance Inside Cells	PRICE SENSITIVE	05/09/17	448.65KB	Share
PYC	Appendix 4E - Preliminary Final Report 30 June 2017	PRICE SENSITIVE	31/08/17	273.09KB	Share
PYC	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/17	48.79KB	Share

PYC Quarterly Activities and Appendix 4C Cash Flow Report
27/01/22	PRICE SENSITIVE	212.81KB	Share
PYC Successful Completion of Key Translational Milestone
16/11/21	PRICE SENSITIVE	190.99KB	Share
PYC Trading Halt
15/11/21	PRICE SENSITIVE	186.73KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	287.47KB	Share
PYC Retina Target Engagement Confirmed in Large Eye
29/09/21	PRICE SENSITIVE	316.13KB	Share
PYC Preliminary Final Report
31/08/21	PRICE SENSITIVE	3.64MB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21	PRICE SENSITIVE	407.7KB	Share
PYC Second Drug Program Progressing Towards Human Trials
08/06/21	PRICE SENSITIVE	389.99KB	Share
PYC Trading Halt
07/06/21	PRICE SENSITIVE	613.05KB	Share
PYC March 2021 Quarterly Report and Cashflow
30/04/21	PRICE SENSITIVE	311.12KB	Share
PYC Lead Investigational Drug Demonstrates Key Improvement
02/03/21	PRICE SENSITIVE	561.42KB	Share
PYC Half Year Accounts and Appendix 4D
26/02/21	PRICE SENSITIVE	695.29KB	Share
PYC Progress US Clinical Stage Company and Corporate Objectives
22/02/21	PRICE SENSITIVE	243.93KB	Share
PYC Quarterly Activities Report and Appendix 4C
29/01/21	PRICE SENSITIVE	424.49KB	Share
PYC Visual Evidence of Lead Drugs Efficacy
16/12/20	PRICE SENSITIVE	302.88KB	Share
PYC Review of Activities and Appendix 4C
26/10/20	PRICE SENSITIVE	230.99KB	Share
PYC Successful Institutional Entitlement Offer and Placement
22/10/20	PRICE SENSITIVE	287.4KB	Share
PYC PYC Business and Equity Raising Presentation
20/10/20	PRICE SENSITIVE	1.52MB	Share
PYC PYC Equity Raising to Raise up to $55 Million
20/10/20	PRICE SENSITIVE	396.91KB	Share
PYC Trading Halt
16/10/20	PRICE SENSITIVE	295.26KB	Share
PYC New Drug for Substantial Unmet Need Added to Pipeline
12/10/20	PRICE SENSITIVE	228.7KB	Share
PYC PYC's Lead Drug Effective in Patient Derived Models Tested
07/10/20	PRICE SENSITIVE	147.03KB	Share
PYC Second Potential Blockbuster Drug Added to PYC's Pipeline
05/10/20	PRICE SENSITIVE	195.93KB	Share
PYC Creation of Novel Gene Therapy Delivery Technology
08/09/20	PRICE SENSITIVE	256.32KB	Share
PYC Appendix 4E Preliminary Final Report
31/08/20	PRICE SENSITIVE	343.8KB	Share
PYC Executive re-structure across global operations
19/08/20	PRICE SENSITIVE	82.17KB	Share
PYC Shareholder Update - Forward View 2020 Milestones
05/08/20	PRICE SENSITIVE	144.91KB	Share
PYC June 2020 Quarterly Activity Report and Cashflow
30/07/20	PRICE SENSITIVE	196.06KB	Share
PYC Successful Dose Response & Toxicity Studies in Lead Program
22/07/20	PRICE SENSITIVE	181.82KB	Share
PYC S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20	PRICE SENSITIVE	223.16KB	Share
PYC March 2020 Quarterly Activities and Cash Flow Report
29/04/20	PRICE SENSITIVE	192.29KB	Share
PYC Successful Efficacy Result on Path to First in Human Studies
01/04/20	PRICE SENSITIVE	564.48KB	Share
PYC Trading Halt
30/03/20	PRICE SENSITIVE	301.8KB	Share
PYC Half Yearly Report and Accounts
28/02/20	PRICE SENSITIVE	580.54KB	Share
PYC Investor Presentation - February 2020
24/02/20	PRICE SENSITIVE	2.07MB	Share
PYC CEO Appointment and Establishment of US Office
12/02/20	PRICE SENSITIVE	125.02KB	Share
PYC Expansion Of Drug Development Pipeline
03/02/20	PRICE SENSITIVE	116.07KB	Share
PYC Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	56.42KB	Share
PYC Quarterly Shareholder Update
06/01/20	PRICE SENSITIVE	90.41KB	Share
PYC Drug Delivery Greater Than 100% More Effective In Animals
02/12/19	PRICE SENSITIVE	213.35KB	Share
PYC Conclusion of Genentech Antimicrobial Collaboration
15/11/19	PRICE SENSITIVE	237.67KB	Share
PYC PYC Increases Shareholding in Vision Pharma
14/11/19	PRICE SENSITIVE	78.29KB	Share
PYC Retail Offer Document
04/11/19	PRICE SENSITIVE	1.06MB	Share
PYC PYC's Institutional Entitlement Offer Closes
04/11/19	PRICE SENSITIVE	79.57KB	Share
PYC Entitlement Offer - Investor Presentation
31/10/19	PRICE SENSITIVE	882.77KB	Share
PYC $26.8m Fully Underwritten Accelerated Entitlement Offer
31/10/19	PRICE SENSITIVE	104.39KB	Share
PYC Trading Halt
31/10/19	PRICE SENSITIVE	116.66KB	Share
PYC Sept 2019 Quarterly Shareholder Update and Appendix 4C
30/10/19	PRICE SENSITIVE	192.66KB	Share
PYC Successful Major Milestone - Human Retina in a Dish Models
09/10/19	PRICE SENSITIVE	368.07KB	Share
PYC Strategic Partnership and Lead Program
01/10/19	PRICE SENSITIVE	204.29KB	Share
PYC Trading Halt
30/09/19	PRICE SENSITIVE	151.93KB	Share
PYC Successful Time-Course Studies in Animals
25/09/19	PRICE SENSITIVE	85.62KB	Share
PYC Successful Competitive Drug Evaluation in Animals
03/09/19	PRICE SENSITIVE	326.49KB	Share
PYC Preliminary Final Report
30/08/19	PRICE SENSITIVE	300.77KB	Share
PYC Successful Time - Course Studies in Animals
22/08/19	PRICE SENSITIVE	105.13KB	Share
PYC Response to ASX Aware Query
07/08/19	PRICE SENSITIVE	738.05KB	Share
PYC Phylogica's Technology is Effective in Human Cells
06/08/19	PRICE SENSITIVE	112.2KB	Share
PYC Company Presentation - July 2019
24/07/19	PRICE SENSITIVE	1.38MB	Share
PYC Operational Update and Appendix 4C
23/07/19	PRICE SENSITIVE	239.37KB	Share
PYC Animal Models - 400% Outperformance of Gold Standard
23/07/19	PRICE SENSITIVE	93.57KB	Share
PYC Break Through Animal Model Results
27/06/19	PRICE SENSITIVE	298.35KB	Share
PYC March 2019 Quarterly Operational Update and App4C
29/04/19	PRICE SENSITIVE	130.46KB	Share
PYC Collaboration Agreement - siRNA delivery
14/03/19	PRICE SENSITIVE	72.14KB	Share
PYC Flagship Program - Successful Animal Models
12/03/19	PRICE SENSITIVE	90.4KB	Share
PYC Half Yearly Report and Accounts
28/02/19	PRICE SENSITIVE	629.87KB	Share
PYC First Competitive Read Out - Peptide Vaccine
08/02/19	PRICE SENSITIVE	95.97KB	Share
PYC Dec 2018 Operational Update and App4C
31/01/19	PRICE SENSITIVE	171.31KB	Share
PYC CEO letter and Operational Update
17/01/19	PRICE SENSITIVE	385.08KB	Share
PYC In Vivo Success - peptide vaccine (Amended Graphics)
06/12/18	PRICE SENSITIVE	149.91KB	Share
PYC In vivo success - peptide vaccine in Herpes Simplex Virus
06/12/18	PRICE SENSITIVE	207.42KB	Share
PYC Successful Delivery of CRIPR/Cas9 into Cells ex vivo
04/12/18	PRICE SENSITIVE	151.1KB	Share
PYC FNA Presentation
23/11/18	PRICE SENSITIVE	1.8MB	Share
PYC AGM Company Presentation
16/11/18	PRICE SENSITIVE	1.39MB	Share
PYC Sept 2018 Quarterly Operations Update and App4C
31/10/18	PRICE SENSITIVE	177.33KB	Share
PYC Fourfold Delivery Improvement in a New Lead Candidate
29/10/18	PRICE SENSITIVE	70.4KB	Share
PYC R&D Tax Incentive Refund
08/10/18	PRICE SENSITIVE	63.48KB	Share
PYC Reinstatement to Official Quotation
12/09/18	PRICE SENSITIVE	403.81KB	Share
PYC Phylogica Recapitalisation
12/09/18	PRICE SENSITIVE	64.61KB	Share
PYC Update on Capital Raising
11/09/18	PRICE SENSITIVE	65.78KB	Share
PYC Suspension from Official Quotation
11/09/18	PRICE SENSITIVE	484.03KB	Share
PYC Trading Halt
07/09/18	PRICE SENSITIVE	274.88KB	Share
PYC Preliminary Final Report
31/08/18	PRICE SENSITIVE	282.38KB	Share
PYC June 2018 Quarterly Operational Update and App4C
31/07/18	PRICE SENSITIVE	224.74KB	Share
PYC Achievement of Major Milestone - In vivo Cre Delivery
30/07/18	PRICE SENSITIVE	80.79KB	Share
PYC Successful In-vivo Results Peptide Vaccine T-Cell Expansion
27/07/18	PRICE SENSITIVE	70.3KB	Share
PYC CEO Update
09/07/18	PRICE SENSITIVE	114.19KB	Share
PYC March 2018 Operational Update and Cashflow
30/04/18	PRICE SENSITIVE	238.56KB	Share
PYC Changes to Board and Management
11/04/18	PRICE SENSITIVE	35.65KB	Share
PYC Trading Halt
09/04/18	PRICE SENSITIVE	141.58KB	Share
PYC Cre Enzyme Delivery Provides Validation & Strategic Value
02/03/18	PRICE SENSITIVE	446.56KB	Share
PYC Dec 2017 Half-year financial statements & Appendix 4D
28/02/18	PRICE SENSITIVE	511.86KB	Share
PYC Dec Quarterly Update and Appendix 4C
31/01/18	PRICE SENSITIVE	602.57KB	Share
PYC Federal R&D Tax Credit Received
11/01/18	PRICE SENSITIVE	76.64KB	Share
PYC FPP Results Effective in Delivering Peptide Cancer Vaccine
08/01/18	PRICE SENSITIVE	109.79KB	Share
PYC Phylogica Strategic Update - Pivot to Platform
04/12/17	PRICE SENSITIVE	123.57KB	Share
PYC Quarterly Update and Appendix 4C
25/10/17	PRICE SENSITIVE	139.47KB	Share
PYC PYC Granted US Patent for Peptides Entering Brain Cells
04/10/17	PRICE SENSITIVE	65.89KB	Share
PYC New Delivery Vehicles Show Improved Performance Inside Cells
05/09/17	PRICE SENSITIVE	448.65KB	Share
PYC Appendix 4E - Preliminary Final Report 30 June 2017
31/08/17	PRICE SENSITIVE	273.09KB	Share
PYC Appendix 4C - quarterly
31/07/17	PRICE SENSITIVE	48.79KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.33		Change 0.080(6.43%)		Mkt cap ! $772.8M

Open	High	Low	Value	Volume
$1.27	$1.35	$1.21	$763.8K	595.4K

Buyers (Bids)

No.	Vol.	Price($)
2	97719	$1.30

Sellers (Offers)

Price($)	Vol.	No.
$1.33	6599	1

View Market Depth

No.	Vol.	Price($)
2	97719	1.300
1	4027	1.240
1	40000	1.220
1	1000	1.200
2	10830	1.190

Price($)	Vol.	No.
1.325	6599	1
1.395	7168	1
1.400	18450	1
1.420	26097	2
1.430	13000	1

Last trade - 16.10pm 08/08/2025 (20 minute delay)

PYC (ASX) Chart

PYC THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories